PATENT COOPERATION TREATY

PCT

REC'D 0-2 MAR 2005

WIPO

PCT

INTERNATIONAL PRELIMINARY REPORT ON PATENTABIL

(Chapter II of the Patent Cooperation Treaty)

(PCT Article 36 and Rule 70)

	olicant's or agent's file reference	FOR FURTUED A	OTION					
100952-1 WO		FOR FURTHER A	CHON	See Form PCT/IPEA/416				
	mational application No. T/GB2004/000099	International filing date 13.01.2004	(day/month/year)	Priority date (day/monthlyear) 16.01.2003				
	mational Patent Classification (IPC) or n							
CO	7D211/70, C07D401/06, C07D40	05/06, C07D409/06, (C07D417/06					
	Applicant ASTRAZENECA AB							
AS	TRAZENECA AB			·				
1.	This report is the international preliminary examination report, established by this International Preliminary Examining Authority under Article 35 and transmitted to the applicant according to Article 36.							
2.	This REPORT consists of a total of 6 sheets, including this cover sheet.							
3.	This report is also accompanied by ANNEXES, comprising:							
	a. Sent to the applicant and to the International Bureau) a total of sheets, as follows:							
	sheets of the description, claims and/or drawings which have been amended and are the basis of this report and/or sheets containing rectifications authorized by this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions).							
	sheets which supersede earlier sheets, but which this Authority considers contain an amendment that goes beyond the disclosure in the international application as filed, as indicated in item 4 of Box No. I and the Supplemental Box.							
	b. (sent to the International Bureau only) a total of (indicate type and number of electronic corrier(s))							
	sequence listing and/or tables related thereto, in computer readable form only, as indicated in the Supplemental Box Relating to Sequence Listing (see Section 802 of the Administrative Instructions).							
	•		- Commission	o mondono).				
_	This							
4.	This report contains indications relating to the following items:							
	Box No. I Basis of the opin	nion .						
	Box No. II Priority							
			ard to novelty, inventiv	e step and industrial applicability				
	☐ Box No. IV Lack of unity of invention ☐ Box No. V Reasoned statement under Article 35(2) with regard to povelty, inventive step or industrial.							
	Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement							
	☐ Box No. VI Certain docume							
		in the international app						
	☐ Box No. VIII Certain observations on the international application							
Date	of submission of the demand		Date of completion of t	this report				
23.0	07.2004		28.02.2005					
Nam	e and mailing address of the International minary examining authority:	al	Authorized Officer					
	European Patent Office - Gitso	hiner Str. 103		good the contract of the contr				
D-10958 Berlin Tel. +49 30 25901 - 0			Hoepfner, W					
_	Fax: +49 30 25901 - 840		Telephone No. +49 30	25901-337				
- Allies and								

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

}

International application No. PCT/GB2004/000099

_						
_	Box No.	Basis of the repo	rt			
1.	. With regard to the language , this report is based on the international application in the language in which it filed, unless otherwise indicated under this item.					age in which it was
	which	report is based on tra n is the language of a ternational search (ur ublication of the intern ternational preliminan	translation furnished der Rules 12.3 and : ational application (u	l for the purposes 23.1(b)) inder Rule 12.4)		e ,
2.	With regard to the elements * of the international application, this report is based on (replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report):					
	Descriptio	n, Pages				
	1-53		as originally filed			
	Claims, Nu	umbers				
	1-13		as originally filed	•		,
	□ a seq	uence listing and/or a	ny related table(s) - :	see Supplementa	al Box Relating to Sequer	nce Listing
3.	the the	imendments have res e description, pages e claims, Nos. e drawings, sheets/fig e sequence listing <i>(sp</i> y table(s) related to s	s ecify):			· .
4.	Suppleme the	report has been estableen made, since they ntal Box (Rule 70.2(condensed description, pages estaims, Nos. end drawings, sheets/figures sequence listing (sport y table(s) related to se	nave been considere)). s ecify):	ed to go beyond t	ts annexed to this report a the disclosure as filed, as	and listed below indicated in the
	* If it	em 4 applies, s	ome or all of th	hese sheets m	mav be marked "supe	rseded "

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No. PCT/GB2004/000099

_						
		x No. III Non-establishment Dicability	of op	inion with regard to novelty, inventive step and industrial		
1.	The obv	ne questions whether the claimed invention appears to be novel, to involve an inventive step (to be non- vious), or to be industrially applicable have not been examined in respect of:				
		the entire international application,				
	\boxtimes	claims Nos. 9,10 (with respect to industrial applicability)				
		because:				
	\boxtimes	the said international application, or the said claims Nos. 9,10 relate to the following subject matter which does not require an international preliminary examination (specify):				
		see separate sheet				
		the description, claims or drawings (indicate particular elements below) or said claims Nos. are so unclear that no meaningful opinion could be formed (specify):				
		the claims, or said claims Nos. are so inadequately supported by the description that no meaningful opinion could be formed.				
		no international search report has been established for the said claims Nos.				
		the nucleotide and/or amino acid sequence listing does not comply with the standard provided for in Annex C of the Administrative Instructions in that:				
		the written form		has not been furnished		
				does not comply with the standard		
		the computer readable form		has not been furnished		
				does not comply with the standard		
		the tables related to the nucleo not comply with the technical re	tide a equire	and/or amino acid sequence listing, if in computer readable form only, do ements provided for in Annex C-bis of the Administrative Instructions.		
		See separate sheet for further	detai	ds .		

Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)

Yes: Claims

1-13

No: Claims

Inventive step (IS)

Yes: Claims

1-13

No: Claims

Industrial applicability (IA)

Yes: Claims

1-8,11-13

No: Claims

2. Citations and explanations (Rule 70.7):

see separate sheet

PCT/GB2004/000099

Re Item III

Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

Claims 9 and 10 relate to subject-matter considered by this Authority to be covered by the provisions of Rule 67.1(iv) PCT. Consequently, the International Examination Authority fully concurs with the objection put forward by the International Search Authority and no opinion will be formulated with respect to the industrial applicability of the subject-matter of these claims (Article 34(4)(a)(I) PCT).

Re Item V

Reasoned statement with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

D1: WO 02/094786 A (WALPOLE CHRISTOPHER; BROWN WILLIAM (CA); WEI ZHONGYONG (CA); ASTRAZEN) 28 November 2002 (2002-11-28)

Novelty

The document D1 discloses diarylmethylidene piperidine derivatives which structurally differ from the diarylmethylidene piperidine derivatives of present claim 1 in that they lack the carbonylamino group at position 3 of the right-hand phenyl residue (see page 1, lines 7, 8; page 2, formula I; page 5, line 17 - page 6, line 27).

Consequently, novelty has to be acknowledged for the subject-matter of the present independent claims 1 and 6-13 and the present dependent claims 2-5.

Inventive step

The distinguishing feature between the novel subject-matter and D1 is the presence of a carbonylamino group at position 3 of the right-hand phenyl residue.

In the absence of any evidence for an unexpected technical effect linked to this feature, the objective problem underlying said subject-matter can merely be seen as the provision of further compounds useful for the provision of medicaments for the treatment of pain, anxiety and functional gastrointestinal disorders.

However, even in the absence of such a technical effect, the presence of inventive activity has to be acknowledged for the claimed solution to this very general problem, namely the modification of the compounds of D1 by exchanging the amino group at the right-hand phenyl moiety with an carbonylamino group, since this solution was not

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY (SEPARATE SHEET)

International application No.

PCT/GB2004/000099

suggested by the prior art.

Industrial applicability

There is no doubt that the subject-matter of the present claims 1-9 and 11-13 is industrially applicable.

However, for the assessment of the present claims 9 and 10 on the question whether they are industrially applicable, no unified criteria exist in the PCT Contracting States. The patentability can also be dependent upon the formulation of the claims. The EPO, for example, does not recognize as industrially applicable the subject-matter of claims to the use of a compound in medical treatment, but may allow, however, claims to a known compound for first use in medical treatment and the use of such a compound for the manufacture of a medicament for a new medical treatment.